Ang A.,University of Colorado at Boulder |
Srivasthan A.,Imperial College London |
Md.-Zain B.M.,Kebangsaan University |
Ismail M.R.B.,National Biodiversity Center |
Meier R.,National University of Singapore
Raffles Bulletin of Zoology | Year: 2012
The banded leaf monkey (Presbytis femoralis femoralis) is critically endangered in Singapore and affected by widespread deforestation in southern Peninsular Malaysia. The Singapore population has recovered from a low of 15-20 to more than 40 individuals, but prior to our study it was unclear how severely the past bottleneck had depleted the genetic diversity of the population. Here, we provide the first analysis of the genetic variability based on seven samples (ca. 20% of population) collected over two years of fieldwork. We find only two haplotypes that differ only in one variable site for the hypervariable region I (HV-I) of the mitochondrial d-loop. Compared to available population-level data for other colobines (proboscis monkey, Yunnan snub-nosed monkey, Sichuan snub-nosed monkey, Angolan black and white colobus), the banded leaf monkey population in Singapore has the lowest number and the most similar haplotypes. This low genetic variability is the next challenge for the conservation of the population. Protected habitats in prospering urban environment may become important sanctuaries for endangered species, but reintroductions may have to be considered in order to restore genetic variability that was lost during past bottlenecks.
Park J.-W.,Center for Liver Cancer |
Finn R.S.,University of California at Los Angeles |
Kim J.S.,Korea University |
Karwal M.,University of Iowa |
And 7 more authors.
Clinical Cancer Research | Year: 2011
Purpose: Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has demonstrated encouraging antitumor activity in preclinical and phase I studies. We performed a phase II open-label study of brivanib as first-line therapy in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma. Experimental Design: Brivanib was administered orally at a dose of 800 mg once daily. The primary objective was 6-month progression-free survival, progression-free survival rate; secondary objectives were tumor response rate, time to response, duration of response, median progression-free survival, median overall survival, disease control rate (complete response, partial response, or stable disease ≥ 42 days), and safety and tolerability. Results: Between March 2007 and May 2009, 55 patients were treated and were evaluable for response. Patients were assessed using modified World Health Organization (mWHO) criteria. According to mWHO criteria and as assessed by Independent Response Review Committee, the six-month progression-free survival rate (95% CI) was 18.2% (9.1%-30.9%). Median progression-free survival (95% CI) was 2.7 months (1.4-3.0). One patient achieved a complete response and three achieved a partial response. Twenty-two had stable disease. Median overall survival (95% CI) was 10 (6.8-15.2) months. Brivanib was generally well tolerated; the most common adverse events included fatigue, hypertension, and diarrhea. Conclusion: Brivanib as first-line therapy demonstrates promising antitumor activity and a manageable safety profile in patients with advanced, unresectable HCC. ©2011 AACR.
PubMed | University Malaysia Sarawak and Kebangsaan University
Type: Journal Article | Journal: Clinics and practice | Year: 2014
The clinical features, autofluorescence, B-scan ultrasonography, optical coherence tomography and fluorescein angiography of the lesion were described. Multiple investigation modalities are needed to confirm the benign nature of the lesion. Careful evaluation and follow-up is crucial to avoid misdiagnosis and erroneous management.
PubMed | University Putra Malaysia, National University of Malaysia, Kebangsaan University and University of Malaya
Type: Journal Article | Journal: Osteoarthritis and cartilage | Year: 2015
Our previous studies on osteoarthritis (OA) revealed positive outcome after chondrogenically induced cells treatment. Presently, the functional improvements of these treated OA knee joints were quantified followed by evaluation of the mechanical properties of the engineered cartilages.Baseline electromyogram (EMGs) were conducted at week 0 (pre-OA), on the locomotory muscles of nine un-castrated male sheep (Siamese long tail cross) divided into controls, adipose-derived stem cells (ADSCs) and bone marrow stem cells (BMSCs), before OA inductions. Subsequent recordings were performed at week 7 and week 31 which were post-OA and post-treatments. Afterwards, the compression tests of the regenerated cartilage were performed.Post-treatment EMG analysis revealed that the control sheep retained significant reductions in amplitudes at the right medial gluteus, vastus lateralis and bicep femoris, whereas BMSCs and ADSCs samples had no further significant reductions (P < 0.05). Grossly and histologically, the treated knee joints demonstrated the presence of regenerated neo cartilages evidenced by the fluorescence of PKH26 tracker. Based on the International Cartilage Repair Society scores (ICRS), they had significantly lower grades than the controls (P < 0.05). The compression moduli of the native cartilages and the engineered cartilages differed significantly at the tibia plateau, patella femoral groove and the patella; whereas at the medial femoral condyle, they had similar moduli of 0.69 MPa and 0.40-0.64 MPa respectively. Their compression strengths at all four regions were within 10 MPa.The tissue engineered cartilages provided evidence of functional recoveries associated to the structural regenerations, and their mechanical properties were comparable with the native cartilage.
PubMed | Sarawak General Hospital and Kebangsaan University
Type: Journal Article | Journal: The Medical journal of Malaysia | Year: 2015
Orbital compartment syndrome (OCS) is a visual threatening ocular emergency. We report a 50-year-old male with acute presentation of OCS, a rare manifestation of idiopathic orbital inflammatory disease. At presentation, high intraocular pressure was reduced by prompt lateral canthotomy and cantholysis. The disease responded to systemic steroids and treatment resulted in good visual outcome. Detail evaluation and early detection and treatment are mandatory to prevent permanent vision loss.
Seow H.F.,University Putra Malaysia |
Yip W.K.,University Putra Malaysia |
Loh H.W.,University Putra Malaysia |
Ithnin H.,University Putra Malaysia |
And 3 more authors.
Pathology and Oncology Research | Year: 2010
Activation of Akt signaling pathway has been documented in various human malignancies, including breast carcinoma. The objective of this study is to determine the incidence of Akt phosphorylation in breast tumours and its relationship with expression of ER-α, ER-β, HER2, Ki-67 and phosphorylated Bcl-2 associated death domain (p-BAD). Immunohistochemical staining was performed to detect these molecules on 43 paraffin-embedded breast tumour tissues with commercially available antibodies. Eighteen (41.9%), 3 (7.0%), 23 (53.5%), 35 (81.4%), 21 (48.8%), 29 (67.4%), and 34 (81.0%) of breast tumours were positive for nuclear ER-α, nuclear ER-β, membranous HER2, cytonuclear p-Akt (Thr308), p-Akt (Ser473), p-BAD and Ki-67, respectively. ER-α expression was inversely correlated with HER2 and Ki-67 (P=0.041 and P=0.040, respectively). The p-Akt (Ser473) was correlated with increased level of p-BAD (Ser136) (P=0.012). No relationship of Akt phosphorylation with HER2, ER-α or ER-β was found. The p-Akt (Ser473) immunoreactivity was significantly higher in stage IV than in stage I or II (P=0.036 or P=0.009). The higher Ki-67 and lower ER-α expression showed an association with patient age of <50 years (P=0.004) and with positive nodal status(P=0.033), respectively. Our data suggest that the Aktphosphorylation and inactivation of its downstream target, BAD may play a role in survival of breast cancer cell. This study does not support the simple model of linear HER2/ PI3K/Akt pathway in breast cancer. © Arányi Lajos Foundation 2009.
Ismail T.,Kebangsaan University
The Medical journal of Malaysia | Year: 2010
Spontaneous pneumothorax (SP) is a common medical condition but continues to be a frequent management problem among doctors. Despite the availability of guidelines on management of SP, studies have shown that the compliance with the guidelines is low. The various treatment options available in treating this condition further confuse doctors on the right approach in managing SP. The objective of this study is to investigate the awareness of the availability of these existing guidelines and to investigate how the doctors involved in the initial management of SP would manage this condition. A self completed questionnaire which included three case scenarios were distributed among doctors in two teaching university hospitals and two large Ministry of Health hospitals. This study showed that there is a lack of awareness of the existing guidelines even among the senior doctors and there is a variation in the initial management of SP. Therefore a locally produced guideline may be beneficial to standardise and improve the management of SP.